To answer BethLabQueen's question specifically:
From a clinical standpoint, Compounded tirzepatide is well-supported by the literature.
The short answer: follow the standard titration protocol and reassess at 4-6 weeks.
The longer answer involves pharmacokinetic considerations around steady-state concentrations, which I am happy to elaborate on if helpful.